Last 2,552 INR
Change Today +15.45 / 0.61%
Volume 304.9K
DRRD On Other Exchanges
Symbol
Exchange
New York
Natl India
Frankfurt
As of 7:05 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

dr. reddy's laboratories (DRRD) Snapshot

Open
2,550
Previous Close
2,537
Day High
2,571
Day Low
2,523
52 Week High
02/28/14 - 2,940
52 Week Low
04/22/13 - 1,859
Market Cap
434.0B
Average Volume 10 Days
427.5K
EPS TTM
98.82
Shares Outstanding
170.0M
EX-Date
07/12/13
P/E TM
25.8x
Dividend
15.00
Dividend Yield
0.59%
Current Stock Chart for DR. REDDY'S LABORATORIES (DRRD)

Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in the operation of biologics business. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. It offers new, synergistic combination, and technology formulations that modifies pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business that includes sales and marketing operations for in-licensed and co-developed dermatology. The company offers its products and services primarily in the areas of gastrointestinal, cardiovascular, pain management, and oncology therapies. It primarily operates in India, the United States, Russia and other countries of the former Soviet Union, Europe, and others. The company has strategic partnership with Galena Biopharma for the development and commercialization of NeuVax, a immunodominant nonapeptide derived from the extracellular domain of the HER2 protein. Dr. Reddy’s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

16,617 Employees
Last Reported Date: 07/10/13
Founded in 1984

dr. reddy's laboratories (DRRD) Top Compensated Officers

Managing Director, Vice-Chairman, Member of T...
Total Annual Compensation: 3.6M
Chairman, Chief Executive Officer, Member of ...
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2013.

dr. reddy's laboratories (DRRD) Key Developments

Dr. Reddy's Laboratories Ltd Gets Approval from US Food and Drug Administration to Sell its Version of Anti-Insomnia Drug Eszopiclone in the US

Dr. Reddy's Laboratories Ltd. got approval from the US Food and Drug Administration (FDA) to sell its version of anti-insomnia drug eszopiclone in the US. Eszopiclone tablets are sold under the brand name Lunesta by Sunovion Pharmaceuticals Inc.

Dr. Reddy's Announces the Launch of Eszopiclone Tablets C-IV

Dr. Reddy's announced that is has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of Lunesta (eszopiclone) tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100.

Dr. Reddy's Laboratories Ltd. Announces Launch of Amoldipine Besylate and Atorvastatin Calcium Tablets

Dr. Reddy's Laboratories Ltd. announced that it has launched Amoldipine Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg a therapeutic equivalent generic version of CADUET tablets in the US market on March 26, 2014, following the approval by the USFDA. The CADUET tablets brand and generic had US sales of approximately $163 million MAT for the most recent twelve months ending January 2014 according to IMS Health.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRD:IN 2,552.20 INR +15.45

DRRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Richter Gedeon Nyrt 3,839 +77.00
Cipla Ltd/India 400.70 INR +3.80
Krka dd Novo mesto €64.20 EUR -0.30
Lupin Ltd 955.65 INR +2.95
Ranbaxy Laboratories Ltd 468.45 INR +2.35
View Industry Companies
 

Industry Analysis

DRRD

Industry Average

Valuation DRRD Industry Range
Price/Earnings 19.9x
Price/Sales 3.4x
Price/Book 5.2x
Price/Cash Flow 19.8x
TEV/Sales 2.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR. REDDY'S LABORATORIES, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.